# **Review Article**



Iran J Public Health, Vol. 53, No.6, Jun 2024, pp.1246-1260

# Adjunctive Drug-Loaded Gel in the Treatment of Periodontitis: A Systematic Evaluation and Meta-Analysis

\*Zhige Li<sup>1,2</sup>, \*Xin Yang<sup>1</sup>, Jiao Wang<sup>1</sup>, Ziyang Qin<sup>1</sup>, Yucheng Meng<sup>1</sup>, Baoping Zhang<sup>1,2,3,4</sup>

1. School (Hospital) of Stomatology, Lanzhou University, Lanzhou, 730000, China

2. Gansu Province Key Lab of Maxillofacial Reconstruction and Intelligent Manufacturing, Lanzhou 730000, China

3. Institute of Biomechanics and Medical Engineering, Lanzhou University, Lanzhou, 730000, China

4. Key Laboratory of Mechanics on Disaster and Environment in Western China, Ministry of Education, Lanzhou University, Lan-

zhou, 730000, China

\*Corresponding Authors: Emails: lzuyx@outlook.com, lizhg@lzu.edu.cn

(Received 08 Apr 2023; accepted 21 Jul 2023)

#### Abstract

**Background:** This meta-analysis aimed to systematically investigate the efficacy of drug-loaded gel adjuncts in the treatment of periodontitis.

**Methods:** A comprehensive search was conducted in six databases, i.e., the China National Knowledge Infrastructure, WanFang Data, VIP Chinese Science and Technology Periodical Database, China Biology Medicine Disc, Cochrane Library, PubMed, and Web of Science, from the inception until Jun 2023. The search focused on randomized controlled trials that examined the application of drug-loaded gels in the treatment of periodontitis. Periodontal probing depth and clinical attachment level were the primary and secondary outcomes, respectively. Stata 15.0 and Review Manager 5.4 were employed to perform the meta-analysis using the selected articles that met the predefined criteria.

**Results:** This study included 16 randomized controlled trials involving 1146 participants. Subgroup analyses based on the follow-up period revealed that the gel-based drug-assisted subgingival root planning intervention had more favorable effects on periodontal probing depth (standardized mean difference=0.50, 95% confidence interval=[0.32, 0.68],  $I^2$ =56.0%, P=0.001) and clinical attachment level (standardized mean difference=0.47, 95% confidence interval=[0.29, 0.66],  $I^2$ =57.0%, P=0.0007) than the subgingival root planning intervention alone. However, subgroup analysis based on the action mechanism of gel drugs showed no statistically significant differences in periodontal probing depth and clinical attachment level between groups.

**Conclusion:** The application of the drug-loaded gel as adjunctive therapy for periodontitis effectively reduced periodontal probing depth and promoted clinical attachment level recovery. The findings provide evidence-based support for the efficacy, security, and rational use of drug-loaded gel in the treatment of periodontitis.

Keywords: Chronic periodontitis; Meta-analysis; Drug-loaded gel; Adjunctive drug therapy; Efficacy evaluation



Copyright © 2024 Li et al. Published by Tehran University of Medical Sciences. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license. (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited

# Introduction

Periodontitis is an inflammatory and destructive disease characterized by the presence of dental plaque biofilms caused by bacterial infection. According to the Global Burden of Diseases Study (2017), oral disorders ranked highest among all included diseases in terms of global agestandardized prevalence for both females and males, with mild periodontitis affecting approximately 50% of the population (1). Periodontitis has become a significant public health concern worldwide, affecting oral health and function; its clinical manifestations include red, swollen, and bleeding gums; formation of periodontal pocket; pus drainage; and resorption of the alveolar bone, which eventually lead to tooth loosening or loss (2-4). Untreated or inadequately treated periodontitis can result in damage to the teeth supporting tissue and subsequent tooth loss, adversely affecting masticatory function, aesthetics, and patients' quality of life (5). Periodontitis is closely associated with cardiovascular diseases (6, 7), neurological diseases (8, 9), metabolic diseases (10, 11), tongue squamous cell carcinoma (12), and oral squamous cell carcinoma (13). Therefore, it is crucial to prioritize the treatment of periodontal disease to improve the oral hygiene status of individuals.

The clinical management of periodontitis is usually based on sequential periodontal therapies, including basic periodontal therapy, periodontal surgical therapy, prosthetic therapy, and supportive periodontal therapy. Among these, basic periodontal treatment is particularly important and mainly includes oral hygiene education; mechanical debridement's, such as supragingival scaling, subgingival scaling, and root planning (SRP); and systemic or topical medication (14-16). Mechanical debridement, such as SRP, removes subgingival calculus and plaque attached to the root surface within the periodontal pocket, resulting in smooth, hard, and clean root surfaces; this procedure reduces local irritation and promotes the attachment and regeneration of periodontal tissue, and it has become the most commonly used clinical non-surgical treatment for periodontitis. However, during SRP, dentists cannot directly remove the dental plaque attached to the root surface or infected cementum under direct vision, resulting in incomplete elimination of infection in shallow periodontal pockets. Therefore, antibiotics are often used as adjuvants after SRP treatment to enhance the efficacy of non-surgical treatment for periodontitis (17). Broad-spectrum or narrow-spectrum antibiotics, alone or in combination, are frequently prescribed as adjuvant therapy for SRP. However, systemic medication has drawbacks, such as poor patient compliance, limited concentration in the periodontal pocket, and the risk of drug resistance, which can affect the therapeutic outcomes for periodontitis. Further research focusing on local administration and dosage is needed to improve the effectiveness of local periodontal treatment (18).

In recent years, in situ injectable sustained-release drugs for the treatment of periodontitis have gradually become a research focus, and gel-based drugs have been widely used because of their excellent adhesion and prolonged sustained-release properties (19, 20). Nevertheless, there are no standardized guidelines for gel-type drugs regarding drug matrix, drug concentration, sustainedrelease time, and biological safety, thereby resulting in varying quality among gel-type drugs and a limited range of clinical applications. Accordingly, this meta-analysis aimed to evaluate the clinical efficacy of drug-loaded gel adjuncts in the SRP treatment for periodontitis. The present findings could provide evidence-based guidance for the rational and more effective use of these medications in clinical practice.

### Methods

#### Search strategy

A computer-based search was conducted in both Chinese and foreign language databases from the inception until Jun 2023. The Chinese databases searched included the China National Knowledge Infrastructure, VIP Chinese Science and Technology Periodical, WanFang, and China Biomedical Literature Databases. English databases searched included the Cochrane Library, Pub-Med, and Web of Science. The search strategy employed a combination of Medical Subject Headings (MeSH) and free terms. In the Chinese databases, the search terms used were "gel or hydrogel" and "periodontitis or periodontitis." As for the English databases, the search terms included "gels" and "periodontitis or periodontitides or pericementitides or pericementitis."

### Inclusion and exclusion criteria

The inclusion criteria were as follows:

<u>Types of studies:</u> randomized controlled trials investigating the use of gel-based drugs for the treatment of periodontitis, published both in China and internationally.

<u>Study participants:</u> adult patients with chronic periodontitis and without any other systemic diseases who had a follow-up period of  $\geq 3$  months.

<u>Types of intervention</u>: The experimental group was treated with gel-based drugs in conjunction with SRP, whereas the control group underwent SRP alone.

<u>Outcomes:</u> primary periodontal probing depth (PPD) and clinical attachment level (CAL).

The exclusion criteria were as follows: patients with systemic diseases other than periodontitis; pregnant or breastfeeding women; periodontal treatment other than the interventions specified in the inclusion criteria within the past three months; articles with duplicate publications or incomplete data, or where the author could not be contacted; nonclinical randomized controlled trials: reviews, retrospective studies, case reports, and conference abstracts; or in vitro tests and animal experiments.

### Risk of bias assessment

Bias risk assessment was conducted following the latest revision of the ROB2.0 standards in 2019. Publication bias was independently assessed by two experts. Five modules, including "randomization process," "Deviation from established interventions," "Missing outcome data," "Outcome measurement," and "selective reporting," were evaluated. The bias from established interventions was divided into two scenarios according to different research purposes: one involved studying the effect of intervention allocation, while the other focused on investigating the effect of intervention compliance. Each project was classified into three levels: "high risk of bias," "low risk of bias," and "concerns."

Two researchers independently extracted data from the included studies. Any disagreements were resolved through discussions with a third researcher. The extracted data included the publication year, first author's name, literature title, sample size, baseline characteristics of the research participants, intervention details, outcome indicators, adverse reactions, and follow-up duration.

### Statistical analysis

The data extracted from the studies were analyzed using Rev Man 5.4 software. The test level for the meta-analysis was set at P=0.05, with the standardized mean difference (SMD) as the combined effect size, and the 95% confidence interval (CI) was calculated. Statistical significance was set at P<0.05. Heterogeneity was assessed using the  $x^2$  test at a significance level of P=0.05 and the  $I^2$  statistic. If heterogeneity was present ( $I^2 \ge$ 50% or P < 0.05), a random-effects model was used for the analysis. In case of no heterogeneity, a fixed-effects model was employed. The reasons for any observed heterogeneity were analyzed and explained. The stability of the included studies was evaluated through subgroup and sensitivity analyses.

### Results

### Study selection

A flowchart of the complete study search and inclusion process is shown in Fig. 1. Initially, 2,998 articles were retrieved through MeSH and free-term searches. These articles were imported into EndNote X9.3.3 for literature management and screening. After removing duplicates, the titles and abstracts of 2,587 articles were reviewed, and 644 articles fulfilled the inclusion criteria. Among these, 159 studies were excluded as they were reviews, systematic reviews, or metaanalyses. Furthermore, 1,746 studies were excluded because they did not address the research questions. Finally, 16 studies were included in the analysis after thoroughly examining titles, abstracts, and full-text articles (Table 1).



Fig. 1: Flow chart for inclusion study search and screening

Author Reference	numbers	Test group measures	Control group measures		ıber of mples	Ger	nder	A	ge	Follow-up time(Month)
(Year)				Т	С	М (Т/С)	F (T/C)	Т	С	
21. (2008)		10% Doxycycline hy- drochloride gel+SRP Xanthan based chlor- hexidine gell+SRP	Only SRP+Placebo gel	30	30	None	None	25-75	25-75	3
32 (2008)		Garcinia mangostana L. pericarp gel+SRP	Only SRP+Placebo gel	64	64	None	None	35-60	35-60	3
23. (2011)		0.125% Moxifloxacin gel+SRP	Only SRP+Placebo	16	15	7/4	9/11	18-75	18-75	3
		0.4% Moxifloxacin gel+SRP	gel	15	15	7/4	8/11			
24		1.25% Moxifloxacin gel+SRP		11	15	6/4	5/11	25.65	25.45	
26. (2012)		Chlorhexidine gel+SRP	Only SRP+Placebo gel	36	36	21/21	15/15	35-65	35-65	4
29 (2013)		1.5%CHX gel+SRP	Only SRP+Placebo gel	10	12	5/9	5/3	36-59	36-71	6
28. (2013)		Spirulina Gel+SRP	Only SRP+Placebo	33	31	None	None	25-45	25-45	4
36. (2014)		Q. brantii and C. sa- tivum gel+SRP	gel Only SRP+Placebo	36	38	None	None	31-52	31-52	3
33. (2016)		Green tea gel+SRP	gel Only SRP+Placebo	23	19	11/11	12/8	34-70	37-74	6
34. (2017)		0.2%Chlorhexidine gel+SRP	gel Only SRP+Placebo	62	62	None	None	None	None	6
25. (2020)		Hyaluronic acid gel+SRP	gel Only SRP+Placebo gel	56	56	29/28	27/28	62-70	61-72	3
27. (2020)		Moxifloxacin and Ibu- profen combination gel+SRP	Only SRP+Placebo gel	20	20	None	None	>18	>18	3
35. (2021)		Tea tree oil gel+SRP	Only SRP+Placebo	15	15	5/5	10/10	21-40	21-40	6
30. (2022)		1.5%MF gel+SRP	gel Only SRP+Placebo gel	15	15	9/6	9/6	25-60	25-60	3
24. (2022)		NaOCl gel+SRP	Only SRP+Placebo	21	18	10/6	11/12	44.60 ± 9.86	50.61 ± 9.31	12
		1%CHX gel+SRP	gel	19	18	11/6	8/12	48.68 ±	50.61 ± 9.31	
31. (2022)		PN+HA gel+SRP	Only SRP+Placebo gel	50	50	None	None	11.63 None	None	12
22. (2023)		Piperacillin plus tazo- bactam gel+SRP	Only SRP+Placebo	21	21	13/7	8/14	50.71±9.56	49.95±6.61	6
-		Doxycycline gel+SRP	gel	22	21	9/7	13/14	47.32±8.08	49.95±6.61	

#### Table 1: Basic information of the included studies

Additionally, in one article published by Gupta (21), the experimental group used two gels, a 10% doxycycline hydrochloride gel and a 1.5% xanthan-gum-based chlorhexidine gel, analyzed separately in the subsequent data statistics. Similar situations were also observed in the studies conducted by Ilyes (22), Flemmig (23), and Radulescu (24), where at least two different gels were utilized. Consequently, although we included 16

articles (21-36), the data analysis considered only 21 results.

#### Risk of bias assessment

The quality assessment of the 16 included articles was performed using the ROB2.0 (Table 2). Among the 16 studies, 10 had a low overall risk, while the remaining had some concerns.

Study ID	Experimental	Comparator	Outcome	Weight	D1a	D1b	D2	D3	D4	D۶	Over all
Gupta, R.	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1		+		+	+	+	+
Rassameemasmaung, S.	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1	4			+	+	+	
Flemmig, Thomas F	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1					+	<b>+</b>	
Zhanhai Dong	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1					$\diamond$	$\diamond$	
Paula Matesanz	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1					$\diamond$	$\diamond$	
Mahendra, J.	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1			$\blacklozenge$	$\diamond$	$\diamond$	$\blacklozenge$	
Yaghini, J.	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1			$\blacklozenge$	$\Rightarrow$	$\diamond$	$\Rightarrow$	
Rattanasuwan, K.	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1			$\blacklozenge$	$\diamond$	$\Rightarrow$	$\diamond$	
B. Vadiati Saberi	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1			$\blacklozenge$	$\diamond$	$\diamond$	$\diamond$	
Ramyasri Kadadasu	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1					+	$\diamond$	
Feizhao Liang	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1					$\diamond$	$\diamond$	
Taalab, M. R	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1					$\diamond$	$\diamond$	
Kuldeep S. Patil	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1			$\blacklozenge$	$\Rightarrow$	$\rightarrow$	$\rightarrow$	
Viorelia Radulescu	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1				$\rightarrow$	$\rightarrow$	$\rightarrow$	+ +
Andrea Pilloni	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1		+		+	+	+	
Ioana Ilyes	Test gel+SRP	Placebo gel+SRP	PPD and CAL	1	+	+		+ + +			+ + +

Table 2: Risk assessment	t form for included	studies based on	ROB2.0 criteria
--------------------------	---------------------	------------------	-----------------

Low risk 💛 Some concerns 🛡 High risk

D1a Randomisation process; D1b Timing of identification or recruitment of participants; D2 Deviations from the intended interventions

D3 Missing outcome data; D4 Measurement of the outcome; D5 Selection of the reported result

#### Comparing PPD before and after treatment

We also compared PPD before and after treatment. The heterogeneity test results are shown in Fig. 2 (P=0.0010,  $I^2$ =56.0%). Our analysis revealed a moderate level of heterogeneity among the studies. Hence, a random effects model was employed, yielding a pooled *SMD* of 0.50 (95% CI=0.32, 0.68). An *SMD* >0 indicates that the gel-based drug-assisted SRP intervention had a better effect on reducing PPD than the SRP intervention alone.



Fig. 2: Forest plots of included studies for which the outcome index was PPD

#### Subgroup analysis

In this study, according to the mechanism of gel drugs in the treatment of periodontitis, the included studies were classified, and a metasubgroup analysis was performed; the results (Fig. 3a) showed that the difference between groups was not statistically significant (P=0.65,  $I^2=0\%$ ). Furthermore, a meta-subgroup analysis was also performed according to the follow-up time after treatment (Fig. 3b). The results revealed a significant difference in the follow-up time between the groups (P=0.02,  $I^2=70.8\%$ ).



Fig. 3: Subgroup analysis of included studies for which the outcome index was PPD. (a) Subgroup analysis of gel types of PPD; (b) Subgroup analysis of follow-up time of PPD

#### Sensitivity analysis

The forest plot of the PPD outcome index indicated the presence of heterogeneity within the overall study population. Sensitivity analysis revealed that the main sources of heterogeneity in the research results were from the studies by Gupta (21) and Kadadasu R (27) (Fig. 4a). The subgroup analysis revealed intergroup heterogeneity in the follow-up time. However, the sensitivity analysis showed that the overall homogeneity of the study improved significantly  $(P=0.84, I^2=0\%)$  after removing the results related to the 12-month follow-up (Fig. 4b).

~		Ge	Is+SRF		0	nly SRF			Std. Mean Difference	Std. Mean Difference
a	Study or Subgroup	Mean	SD	Total		SD		Weight	IV. Random. 95% CI	IV. Random. 95% Cl
	Andrea Pilloni 2022	2.08	1.24	50	1.94	1.19	50		0.11 [-0.28, 0.51]	
	B. Vadiati Saberi 2017	1.05	0.78	62	0.4	0.69	62	8.7%	0.88 [0.51, 1.25]	
	Feizhao Liang 2020	1.26	0.49	56	1.03	0.5	56	8.5%	0.46 [0.09, 0.84]	
	Gupta, R(CHX) 2008	2.76	1.25	30	1.73	0.94	30		0.92 [0.39, 1.45]	
	Gupta, R(DH) 2008	2.75	1.33	30	1.73	0.94	30	0.0%	0.87 [0.34, 1.41]	
	Ioana Ilyes 2023 (14%Doxycycline)	1.67	0.47	21	1.47	0.62	21	4.9%	0.36 [-0.25, 0.97]	
	Ioana Ilyes 2023 (Piperacillin)	1.68	0.49	21	1.47	0.62	21	4.9%	0.37 [-0.24, 0.98]	
	Kuldeep S. Patil 2022	2.6	0.737	15	1.8	1.082	15	3.6%	0.84 [0.09, 1.59]	
	Mahendra, J 2013	1.57	0.55	33	0.84	0.91	31	6.0%	0.97 [0.45, 1.49]	
	Paula Matesanz 2013 Ramyasri Kadadasu 2020	0.32 2.85	0.15 0.54	10 20	0.22 1.83	0.59 0.55	10 20	2.8% 0.0%	0.22 [-0.66, 1.10] 1.83 [1.08, 2.58]	
	Ramyash Rababasu 2020 Rassameemasmaung, S 2008	2.00 1.98	0.54	20 64	1.65	0.55	20 64	8.9%	0.66 [0.30, 1.01]	
	Rattanasuwan, K 2016	2.71	1.16	23	2.67	1.04	19		0.04 [-0.57, 0.64]	
	Taalab, M. R 2021	3.5	1.01	15	2.9	0.95	15	3.7%	0.60 [-0.14, 1.33]	
	Thomas F. Flemmig (0.125%) 2011	1.1	1.1	16	1	0.6	15		0.11 [-0.60, 0.81]	<del></del>
	Thomas F. Flemmig (0.4%) 2011	1.5	0.6	15	1	0.6	15	3.6%	0.81 [0.06, 1.56]	
	Thomas F. Flemmig (1.25%) 2011	1.2	0.4	11	1	0.6	15	3.4%	0.37 [-0.42, 1.15]	
	Viorelia Radulescu (1%CHX) 2022	0.61	0.52	21	0.75	0.58	21	4.9%	-0.25 [-0.86, 0.36]	
	Viorelia Radulescu (NaOCI) 2022	0.81	0.38	21	0.75	0.58	21	4.9%	0.12 [-0.49, 0.73]	
	Yaghini J 2014	1.64	0.77	36	1.58	0.87	38	7.0%	0.07 [-0.38, 0.53]	_ <b>_</b>
	Zhanhai Dong 2012	5.85	3.15	36	4.76	4.07	36	6.9%	0.30 [-0.17, 0.76]	
	Total (95% CI)			526			525	100.0%	0.40 [0.24, 0.57]	
	Heterogeneity: Tau <sup>2</sup> = 0.04; Chi <sup>2</sup> = 27.3		' (P = 0	.05); l²	= 38%				·	-2 -1 0 1 2
	Test for overall effect: Z = 4.85 (P < 0.0	0001)								Gels+SRP [experimental] Only SRP [control]
1.		6.	Is+SRP		0	IV SRP			Std. Mean Difference	Std. Mean Difference
D	Study or Subgroup	Mean			Mean			Weight	IV. Random, 95% Cl	IV. Random, 95% CI
-	1.3.1 Three Months									
	Feizhao Liang 2020	1.26	0.49	56	1.03	0.5	56	8.2%	0.46 [0.09, 0.84]	
	Gupta, R(CHX) 2008	2.76	1.25	30	1.73	0.94	30	6.0%	0.92 [0.39, 1.45]	
	Gupta, R(DH) 2008	2.75	1.33	30	1.73	0.94	30	6.0%	0.87 [0.34, 1.41]	
	Ramyasri Kadadasu 2020	2.85	0.54	20	1.83	0.55	20	4.0%	1.83 [1.08, 2.58]	
	Rassameemasmaung, S 2008	1.98	0.72	64	1.52	0.67	64	8.5%	0.66 [0.30, 1.01]	
	Thomas F. Flemmig (0.125%) 2011	1.1	1.1	16	1	0.6	15	4.3%	0.11 [-0.60, 0.81]	
	Thomas F. Flemmig (0.4%) 2011	1.5	0.6	15	1	0.6	15	4.0%	0.81 [0.06, 1.56]	
	Thomas F. Flemmig (1.25%) 2011	1.2	0.4	11	1	0.6	15	3.7%	0.37 [-0.42, 1.15]	
	Yaghini J 2014	1.64	0.77	36 278	1.58	0.87	38 283	7.0% 51.8%	0.07 [-0.38, 0.53]	
	Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.12; Chi <sup>2</sup> = 21.05	df = 0	- 0 0		- 60%		283	51.6%	0.65 [0.36, 0.94]	-
	Test for overall effect: Z = 4.33 (P < 0.00		P - 0.0	07), 1-	- 02 %					
		,								
	1.3.2 Four Months									
	Mahendra, J 2013	1.57	0.55	33	0.84	0.91	31	6.2%	0.97 [0.45, 1.49]	
	Zhanhai Dong 2012	5.85	3.15	36 69	4.76	4.07	36	6.9%	0.30 [-0.17, 0.76]	
	Subtotal (95% CI)	ar a cr			004		67	13.1%	0.62 [-0.04, 1.28]	
	Heterogeneity: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 3.55, Test for overall effect: Z = 1.85 (P = 0.06		' = 0.06	); 1- = 7	2%					
		,								
	1.3.3 Six Months									
	B. Vadiati Saberi 2017	1.05	0.78	62	0.4	0.69	62	8.3%	0.88 [0.51, 1.25]	
	Ioana Ilyes 2023 (14%Doxycycline)	1.09	0.6	21	0.85	0.61	21	5.2%	0.39 [-0.22, 1.00]	
	Ioana Ilyes 2023 (Piperacillin)	1.68	0.49	21	1.47	0.62	21	5.2%	0.37 [-0.24, 0.98]	
	Kuldeep S. Patil 2022	2.6	0.737	15		1.082	15	4.0%	0.84 [0.09, 1.59]	
	Paula Matesanz 2013 Rattanasuwan, K 2016	0.32	0.15	10 23	0.22 2.67	0.59 1.04	10 19	3.2% 5.2%	0.22 [-0.66, 1.10]	
	Rattanasuwan, K 2016 Taalab, M. R 2021	2.71	1.16	23	2.67	1.04	19	5.2% 4.1%	0.04 [-0.57, 0.64] 0.60 [-0.14, 1.33]	
	Subtotal (95% CI)	5.5	1.01	167	2.0	0.30	163	35.1%	0.53 [0.27, 0.79]	◆
	Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 7.49, Test for overall effect: Z = 4.05 (P < 0.00		9 = 0.28	);  2 = 2	:0%					
	1.3.4 Twevel Months			-			-			
	Andrea Pilloni 2022	2.08	1.24	50	1.94	1.19	50	0.0%	0.11 [-0.28, 0.51]	
	Viorelia Radulescu (1%CHX) 2022 Viorelia Radulescu (NaOCI) 2022	0.61 0.81	0.52	21 21	0.75 0.75	0.58 0.58	21 21	0.0% 0.0%	-0.25 [-0.86, 0.36] 0.12 [-0.49, 0.73]	
	Subtotal (95% CI)	0.81	0.38	21	0.75	0.58	21	0.0%	0.12 [-0.49, 0.73] Not estimable	
	Subtotal (95% CI) Heterogeneity: Not applicable			U			U		Not estimable	
	Test for overall effect: Not applicable									
	. oct of overall encourter applicable									
	Total (95% CI)			514			513	100.0%	0.59 [0.41, 0.77]	•
	Heterogeneity: Tau <sup>2</sup> = 0.07; Chi <sup>2</sup> = 32.18	B, df = 17	(P = 0.	01); l²	= 47%				-	-2 -1 0 1 2
	Test for overall effect: Z = 6.37 (P < 0.00									Gels+SRP [experimental] Only SRP [control]
	Test for subgroup differences: Chi <sup>2</sup> = 0.3	36. df = 2	(P = 0.	84). <b>I</b> ² :	= 0%					

Fig. 4: Sensitivity analysis of included studies in which the outcome index was PPD. (a) Overall study sensitivity analysis of PPD; (b) Sensitivity analysis of follow-up time for PPD

#### Comparing CAL before and after treatment

We further assessed the CAL before and after treatment in the nine included studies. The heterogeneity test results are shown in Fig. 5 (P=0.0007, I<sup>2</sup>=57.0%). The heterogeneity between studies was moderate, and a random-

effects model was thus employed, yielding a pooled *SMD* of 0.47 (95% *CI*=0.29-0.66), indicating that the gel-based drug-assisted SRP intervention had a more favorable effect on CAL than the SRP intervention alone.

	Ge	els+SRF	<b>)</b>	0	nly SRF	•		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV. Random, 95% CI
Andrea Pilloni 2022	0.5	1.85	50	0.36	1.8	50	6.3%	0.08 [-0.32, 0.47]	+
B. Vadiati Saberi 2017	0.44	1.07	62	0.07	0.95	62	6.7%	0.36 [0.01, 0.72]	
Feizhao Liang 2020	1.6	0.68	56	1.3	0.69	56	6.5%	0.43 [0.06, 0.81]	
Gupta, R(CHX) 2008	2.03	1.06	30	0.86	0.68	30	4.9%	1.30 [0.74, 1.86]	
Gupta, R(DH) 2008	1.73	0.9	30	0.86	0.68	30	5.0%	1.08 [0.53, 1.62]	
loana Ilyes 2023 (14%Doxycycline)	1.09	0.6	21	0.85	0.61	21	4.5%	0.39 [-0.22, 1.00]	+
oana Ilyes 2023 (Piperacillin)	1.1	0.54	21	0.85	0.61	21	4.5%	0.43 [-0.19, 1.04]	<del></del>
Kuldeep S. Patil 2022	1	0.655	15	0.8	0.676	15	3.7%	0.29 [-0.43, 1.01]	- <del></del>
Mahendra, J 2013	1.13	1.08	33	0.68	0.94	31	5.4%	0.44 [-0.06, 0.93]	<u>––</u>
Paula Matesanz 2013	0.3	0.31	10	0.01	0.37	12	2.9%	0.81 [-0.07, 1.69]	<u> </u>
Ramyasri Kadadasu 2020	2.85	0.57	20	1.95	0.57	20	3.8%	1.55 [0.83, 2.26]	
Rassameemasmaung, S 2008	1.33	1.05	64	1.2	1.16	64	6.8%	0.12 [-0.23, 0.46]	+-
Rattanasuwan, K 2016	2.22	1.69	23	2.17	1.56	19	4.5%	0.03 [-0.58, 0.64]	
Faalab, M. R 2021	2.9	0.5	15	2.2	0.62	15	3.4%	1.21 [0.42, 2.00]	——
Thomas F. Flemmig (0.125%) 2011	0.7	0.9	16	0.6	0.5	15	3.8%	0.13 [-0.57, 0.84]	- <del>-</del>
Thomas F. Flemmig (0.4%) 2011	0.8	0.4	15	0.6	0.5	15	3.7%	0.43 [-0.30, 1.15]	+
homas F. Flemmig (1.25%) 2011	0.8	0.4	11	0.6	0.5	15	3.4%	0.42 [-0.37, 1.21]	<del></del>
Viorelia Radulescu (1%CHX) 2022	0.39	0.38	21	0.57	0.5	21	4.5%	-0.40 [-1.01, 0.21]	+
/iorelia Radulescu (NaOCI) 2022	0.7	0.4	21	0.57	0.5	21	4.5%	0.28 [-0.33, 0.89]	+
Yaghini J 2014	2.25	0.71	36	1.92	0.82	38	5.7%	0.42 [-0.04, 0.89]	<u></u>
Zhanhai Dong 2012	1.57	1.28	36	0.49	1.59	36	5.6%	0.74 [0.26, 1.22]	
Total (95% CI)			606			607	100.0%	0.47 [0.29, 0.66]	•
Heterogeneity: Tau <sup>2</sup> = 0.10; Chi <sup>2</sup> = 46.2	7, df = 20	0 (P = 0)	.0007);	<sup>2</sup> = 579	%				
Test for overall effect: Z = 5.07 (P < 0.0			,						-4 -2 0 2 4 Gels+SRP [experimental] SRP [control]

Fig. 5: Forest plots of included studies for which the outcome index was CAL

#### Subgroup analysis

The present study also conducted a subgroup analysis based on the action mechanism of gel drugs and follow-up time after treatment. The subgroup analysis based on the action mechanism of gel drugs (Fig. 6a) showed no statistically significant difference among the groups (P=0.21,  $I^2=33.2\%$ ). However, the subgroup analysis based on follow-up time revealed (Fig. 6b) heterogeneity among different follow-up times (P=0.04,  $I^2=63.7\%$ ).



Fig. 6: Subgroup analysis of included studies for which the outcome index was CAL. (a)Subgroup analysis of gel types of CAL; (b) Subgroup analysis of follow-up time of CAL.

#### Sensitivity analysis

When CAL was used as an outcome indicator, overall heterogeneity was observed among the studies. The sensitivity analysis found that the studies by Gupta R (21) and Kadadasu R (27) had a significant influence on heterogeneity; after excluding these two studies, the overall homogeneity was significantly improved (Fig. 7a). Furthermore, the sensitivity analysis demonstrated that the heterogeneity of the included studies was significantly reduced (P=0.52,  $I^2=0\%$ ) after excluding the results from studies with a 12-month follow-up duration (Fig. 7b).

Study or Subgroup		els+SR			Only SR	. <b>F</b>		Std. Mean Difference	Std. Mean Difference
orady or orangioup	Mean	SD	Tota	Mean	n SD	Tota	al Weight	IV. Random. 95% C	IV. Random, 95% CI
Andrea Pilloni 2022	0.5	1.85	50	0.36	6 1.8	50	9.2%	0.08 [-0.32, 0.47]	
B. Vadiati Saberi 2017	0.44	1.07	62	0.0	7 0.95	62	2 10.8%	0.36 [0.01, 0.72]	
Feizhao Liang 2020	1.6	0.68	56	1.3	3 0.69	56	6 9.9%	0.43 [0.06, 0.81]	
Gupta, R(CHX) 2008	2.03	1.06	30	0.8	6 0.68	30	0.0%	1.30 [0.74, 1.86]	
Gupta, R(DH) 2008	1.73	0.9	30	0.8	6 0.68	30	0.0%	1.08 [0.53, 1.62]	
Ioana Ilyes 2023 (14%Doxycycline)	1.09	0.6	21	0.8	5 0.61	2	1 4.3%	0.39 [-0.22, 1.00]	+
Ioana Ilyes 2023 (Piperacillin)	1.1	0.54	21	0.8	5 0.61	2	1 4.3%	0.43 [-0.19, 1.04]	+
Kuldeep S. Patil 2022	1	0.655	15					0.29 [-0.43, 1.01]	
Mahendra, J 2013	1.13	1.08	33					0.44 [-0.06, 0.93]	
Paula Matesanz 2013	0.3	0.31	10					0.81 [-0.07, 1.69]	
	2.85	0.57	20						
Ramyasri Kadadasu 2020								1.55 [0.83, 2.26]	
Rassameemasmaung, S 2008	1.33	1.05	64					0.12 [-0.23, 0.46]	
Rattanasuwan, K 2016	2.22		23					0.03 [-0.58, 0.64]	
Taalab, M. R 2021	2.9	0.5	15					1.21 [0.42, 2.00]	
Thomas F. Flemmig (0.125%) 2011	0.7	0.9	16					0.13 [-0.57, 0.84]	
Thomas F. Flemmig (0.4%) 2011	0.8	0.4	15					0.43 [-0.30, 1.15]	
Thomas F. Flemmig (1.25%) 2011	0.8	0.4	11					0.42 [-0.37, 1.21]	
Viorelia Radulescu (1%CHX) 2022	0.39	0.38	21	0.5	7 0.5	2	1 4.3%	-0.40 [-1.01, 0.21]	+
Viorelia Radulescu (NaOCI) 2022	0.7	0.4	21	0.5	7 0.5	2	1 4.4%	0.28 [-0.33, 0.89]	+
Yaghini J 2014	2.25	0.71	36	1.9	2 0.82	: 34	8 7.1%	0.42 [-0.04, 0.89]	
Zhanhai Dong 2012	1.57	1.28	36					0.74 [0.26, 1.22]	
0			50					(,)	
Total (95% CI)			526			527	7 100.0%	0.33 [0.20, 0.46]	•
Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 19.4	l6 df = 1	7 (P = 0							
Test for overall effect: Z = 4.83 (P < 0.0		. (		10 /					-4 -2 0 2
									Gels+SRP [experimental] SRP [control]
	Gel	s+SRP		On	ly SRP		Std	. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean		otal I			otal V		V. Random, 95% Cl	IV. Random, 95% CI
2.3.1 Three Months									
Feizhao Liang 2020	1.6	0.68	56	1.3	0.69	56	8.0%	0.43 [0.06, 0.81]	
Gupta, R(CHX) 2008	2.03	1.06	30	0.86	0.68	30	5.7%	1.30 [0.74, 1.86]	
Gupta, R(DH) 2008	1.73	0.9	30	0.86	0.68	30	5.9%	1.08 [0.53, 1.62]	
Ramyasri Kadadasu 2020	2.85	0.57	20	1.95	0.57	20	4.3%	1.55 [0.83, 2.26]	
	2.65	1.05	64		1.16	20 64	4.3% 8.4%	0.12 [-0.23, 0.46]	
Rassameemasmaung, S 2008				1.2					
Thomas F. Flemmig (0.125%) 2011	0.7	0.9	16	0.6	0.5	15	4.4%	0.13 [-0.57, 0.84]	-
	0.8	0.4	15	0.6	0.5	15	4.3%	0.43 [-0.30, 1.15]	
Thomas F. Flemmig (1.25%) 2011	0.8	0.4	11	0.6	0.5	15	3.8%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21]	
Thomas F. Flemmig (0.4%) 2011 Thomas F. Flemmig (1.25%) 2011 Yaghini J 2014			11 36		0.5 0.82	15 36	3.8% 6.8%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J 2014 Subtotal (95% CI)	0.8 2.25	0.4 0.71	11 36 278	0.6 1.92	0.5 0.82	15 36	3.8%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J 2014 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 26.08	0.8 2.25 , df = 8 (f	0.4 0.71	11 36 278	0.6 1.92	0.5 0.82	15 36	3.8% 6.8%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J 2014 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0,16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00	0.8 2.25 , df = 8 (f	0.4 0.71	11 36 278	0.6 1.92	0.5 0.82	15 36	3.8% 6.8%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J 2014 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months	0.8 2.25 , df = 8 (8 01)	0.4 0.71 P = 0.00	11 36 278 1); I <sup>2</sup> =	0.6 1.92 69%	0.5 0.82	15 36 281	3.8% 6.8% 51.6%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J 2014 Subtotal (85% CI) Heterogeneity: Tau <sup>a</sup> = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J 2013	0.8 2.25 , df = 8 (f 01) 1.13	0.4 0.71 P = 0.00	11 36 278 1); I <sup>2</sup> =	0.6 1.92 69% 0.68	0.5 0.82 0.94	15 36 281 31	3.8% 6.8% 51.6% 6.4%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J 2014 Bubtotai (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J 2013 Zhanhai Dong 2012	0.8 2.25 , df = 8 (8 01)	0.4 0.71 P = 0.00	11 36 278 1); I <sup>2</sup> = 33 36	0.6 1.92 69%	0.5 0.82	15 36 281 31 36	3.8% 6.8% 51.6% 6.4% 6.7%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J 2014 Subiotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J 2013 Zhanhai Dong 2012 Subiotal (95% CI)	0.8 2.25 , df = 8 (f 01) 1.13 1.57	0.4 0.71 P = 0.00 1.08 1.28	11 36 278 1); l <sup>2</sup> = 33 36 69	0.6 1.92 69% 0.68 0.49	0.5 0.82 0.94	15 36 281 31 36	3.8% 6.8% 51.6% 6.4%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J 2014 Bubtotal (85% Cl) Heterogeneity: Tau <sup>2</sup> = 0.16: Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J 2013 Zhanhai Dong 2012 Subtotal (85% Cl) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.74,	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P	0.4 0.71 P = 0.00 1.08 1.28	11 36 278 1); l <sup>2</sup> = 33 36 69	0.6 1.92 69% 0.68 0.49	0.5 0.82 0.94	15 36 281 31 36	3.8% 6.8% 51.6% 6.4% 6.7%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J 2014 Bubtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J 2013 Zhanhai Dong 2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.74,	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P	0.4 0.71 P = 0.00 1.08 1.28	11 36 278 1); l <sup>2</sup> = 33 36 69	0.6 1.92 69% 0.68 0.49	0.5 0.82 0.94	15 36 281 31 36	3.8% 6.8% 51.6% 6.4% 6.7%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J 2014 Subtotal (85% Cl) Heterogeneity: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J 2013 Zhanhai Dong 2012 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P	0.4 0.71 P = 0.00 1.08 1.28	11 36 278 1); l <sup>2</sup> = 33 36 69	0.6 1.92 69% 0.68 0.49	0.5 0.82 0.94	15 36 281 31 36	3.8% 6.8% 51.6% 6.4% 6.7%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22]	
Thomas F. Flemming (1.25%) 2011 Yaghini J 2014 Subtotal (95% CI) Heterogeneily: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J 2013 Zhanhai Dong 2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months	0.8 2.25 (ff = 8 (f 01) 1.13 1.57 df = 1 (P 07)	0.4 0.71 P = 0.00 1.08 1.28 = 0.39);	11 36 278 1);   <sup>2</sup> = 33 36 69   <sup>2</sup> = 0%	0.6 1.92 69% 0.68 0.49	0.5 0.82 0.94 1.59	15 36 281 31 36 67	3.8% 6.8% 51.6% 6.4% 6.7% 13.1%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.64 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94]	
Thomas F. Flemming (1.25%) 2011 Yaghini J 2014 Subiotal (85% CI) Heterogeneity: Tau" = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J 2013 Zhanhai Dong 2012 Subiotal (95% CI) Heterogeneity: Tau" = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44	0.4 0.71 P = 0.00 1.08 1.28 = 0.39); 1.07	11 36 278 1);   <sup>2</sup> = 33 36 69   <sup>2</sup> = 09	0.6 1.92 69% 0.68 0.49 6	0.5 0.82 0.94 1.59	15 36 281 31 36 67 62	3.8% 6.8% 51.6% 6.4% 6.7% 13.1% 8.3%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J.2017 Subtotal (95% CI) Heterogenelty: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J.2013 Zhanhai Dong 2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Joana Ilyes 2023 (14%Doxycoline)	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09	0.4 0.71 P = 0.00 1.08 1.28 = 0.39); 1.07 0.6	11 36 278 1);   <sup>2</sup> = 33 36 69   <sup>2</sup> = 09	0.6 1.92 69% 0.68 0.49 6	0.5 0.82 0.94 1.59 0.95 0.61	15 36 281 31 36 67 62 21	3.8% 6.8% 51.6% 6.4% 6.7% 13.1% 8.3% 5.2%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94]	
Thomas F. Flemming (1.25%) 2011 Yaghini J.2014 Subtotal (95% CI) Heterogeneity: Tau'e $= 0.16$ ; Chi <sup>a</sup> $= 26.08$ Test for overall effect: Z $= 3.81$ (P $= 0.00$ 2.3.2 Four Months Mahendra, J.2013 Zhanhai Dong 2012 Subtotal (95% CI) Heterogeneity: Tau'e $= 0.00$ ; Chi <sup>a</sup> $= 0.74$ , Test for overall effect: Z $= 3.38$ (P $= 0.002$ 2.3.3 Six Months B. Vadiati Saberi 2017 Ioana Ilyse 2023 (Piperacillin)	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1	$\begin{array}{c} 0.4\\ 0.71\\ \hline \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ $	11 36 278 1);   <sup>2</sup> = 33 36 69   <sup>2</sup> = 09 62 21 21	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85	0.5 0.82 0.94 1.59 0.95 0.61 0.61	15 36 281 31 36 67 62 21 21	3.8% 6.8% 51.6% 6.4% 6.7% 13.1% 8.3% 5.2% 5.2%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.58 [0.25, 0.94] 0.36 [0.01, 0.72] 0.38 [-0.22, 1.00] 0.43 [-0.18, 1.04]	
Thomas F. Flemming (1.25%) 2011 Yaghini J 2014 Subiotal (85% CI) Heterogeneity: Tau'e = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J 2013 Zhanhai Dong 2012 Subiotal (95% CI) Heterogeneity: Tau'e = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Ioana Ilyes 2023 (14%Doxycycline) Ioana Ilyes 2023 (14%Doxycycline) Ioana Ilyes 2023 (14%Doxycycline) Ioana Ilyes 2023 (14%Doxycycline)	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1	$\begin{array}{c} 0.4\\ 0.71\\ \hline\\ = 0.00\\ 1.08\\ 1.28\\ = 0.39);\\ 1.07\\ 0.6\\ 0.54\\ 0.655\end{array}$	11 36 278 1);   <sup>2</sup> = 33 36 69   <sup>2</sup> = 09 62 21 21 15	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.8	0.5 0.82 0.94 1.59 0.95 0.61 0.61 0.61	15 36 281 31 36 67 62 21 21 15	3.8% 6.8% 51.6% 6.4% 6.7% 13.1% 8.3% 5.2% 4.3%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.39 [-0.22, 1.00] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J.2014 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.16; Ch <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J.2013 Zhanhai Dong 2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Ioana Ilyes 2023 (14%Doxycycline) Ioana Ilyes 2023 (Piperacillin) Kuldeep S. Patil 2022 Paula Matesanz 2013	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1 1 4 0.3	$\begin{array}{c} 0.4 \\ 0.71 \\ \hline \end{array}$ $= 0.00 \\ 1.08 \\ 1.28 \\ = 0.39); \\1.07 \\ 0.6 \\ 0.54 \\ 0.655 \\ 0.31 \end{array}$	11 36 278 1); l <sup>2</sup> = 33 36 69 l <sup>2</sup> = 09 62 21 21 15 10	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.85 0.85 0.85	0.5 0.82 0.94 1.59 0.95 0.61 0.676 0.676 0.37	15 36 281 31 36 67 62 21 21 15 12	3.8% 6.8% 51.6% 6.4% 6.7% 13.1% 8.3% 5.2% 5.2% 5.2% 4.3% 3.3%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.39 [-0.22, 1.00] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01] 0.81 [-0.07, 1.69]	
Thomas F. Flemming (1.25%) 2011 Yaghini J 2014 Subiotal (85% Cl) Heterogeneity: Tau'e = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J 2013 Zhanhai Dong 2012 Subiotal (95% Cl) Heterogeneity: Tau'e = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Ioana Ilyes 2023 (14%Doxycycline) Ioana Ilyes 2023 (14%Doxycycline) Kuldeep S, Patil 2022 Paula Matesanz 2013 Rattanasuwa, K 2016	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1 1.1 0.3 2.22	$\begin{array}{c} 0.4\\ 0.71\\ \hline \\ \end{array}$	11 36 278 1);   <sup>2</sup> = 33 36 69   <sup>2</sup> = 09 62 21 15 10 23	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.81 2.17	0.5 0.82 0.94 1.59 0.61 0.61 0.661 0.67 1.56	15 36 281 31 36 67 62 21 21 15 12 19	3.8% 6.8% 51.6% 6.4% 6.7% 13.1% 8.3% 5.2% 4.3% 3.3%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.39 [-0.22, 1.00] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01] 0.81 [-0.07, 1.69] 0.03 [-0.58, 0.64]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J.2014 Subtotal (95% CI) Heterogeneily: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J.2013 Zhanhai Dong 2012 Subtotal (95% CI) Heterogeneily: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Ioana Ilyes 2023 (14%Doxycycline) Ioana Ilyes 2023 (14%Doxycycline) Taula Matesanz 2013 Rattanasuwan, K 2016 Taalab, M. R 2021	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1 1 4 0.3	$\begin{array}{c} 0.4 \\ 0.71 \\ \hline \end{array}$ $= 0.00 \\ 1.08 \\ 1.28 \\ = 0.39); \\1.07 \\ 0.6 \\ 0.54 \\ 0.655 \\ 0.31 \end{array}$	11 36 278 1):   <sup>2</sup> = 33 36 69   <sup>2</sup> = 0? 62 21 21 15 10 23 15	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.85 0.85 0.85	0.5 0.82 0.94 1.59 0.61 0.61 0.676 0.67 1.56 0.62	15 36 281 31 36 67 62 21 21 15 12 19 15	3.8% 6.8% 51.6% 6.7% 13.1% 8.3% 5.2% 4.3% 3.3% 5.3% 3.8%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.38 [-0.22, 1.00] 0.44 [-0.07, 1.69] 0.39 [-0.43, 1.01] 0.51 [-0.07, 1.69] 0.31 [-0.57, 0.64] 1.21 [0.42, 2.00]	
Thomas F. Flemming (1.25%) 2011 Yaghini J 2014 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.16; Ch <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J 2013 Zhanhai Dong 2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Ioana Ilyes 2023 (Piperacillin) Kuldeep S. Patil 2022 Paula Matesanz 2013 Ratianasuwan, K 2016 Taalab, M. R 2021 Subtotal (95% CI)	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1 1 0.3 2.22 2.9	$\begin{array}{c} 0.4\\ 0.71\\ \end{array}$ = 0.00 $\begin{array}{c} 1.08\\ 1.28\\ = 0.39);\\ \begin{array}{c} 1.07\\ 0.6\\ 0.54\\ 0.655\\ 0.31\\ 1.69\\ 0.5 \end{array}$	11 36 278 1): $ ^2 =$ 33 36 69 $ ^2 = 09$ 62 21 21 15 10 23 15 167	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.85 0.85 0.85 0.01 2.17 2.2	0.5 0.82 0.94 1.59 0.61 0.61 0.676 0.67 1.56 0.62	15 36 281 31 36 67 62 21 21 15 12 19	3.8% 6.8% 51.6% 6.4% 6.7% 13.1% 8.3% 5.2% 4.3% 3.3%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.39 [-0.22, 1.00] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01] 0.81 [-0.07, 1.69] 0.03 [-0.58, 0.64]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J.2014 Subtotal (95% CI) Heterogeneliy: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J.2013 Zhanhai Dong 2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Ioanal Ilyes 2023 (14%Doxycycline) Ioanal Ilyes 2023 (14%D	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1 1.1 0.3 2.22 2.9 df = 6 (P	$\begin{array}{c} 0.4\\ 0.71\\ \end{array}$ = 0.00 $\begin{array}{c} 1.08\\ 1.28\\ = 0.39);\\ \begin{array}{c} 1.07\\ 0.6\\ 0.54\\ 0.655\\ 0.31\\ 1.69\\ 0.5 \end{array}$	11 36 278 1): $ ^2 =$ 33 36 69 $ ^2 = 09$ 62 21 21 15 10 23 15 167	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.85 0.85 0.85 0.01 2.17 2.2	0.5 0.82 0.94 1.59 0.61 0.61 0.676 0.67 1.56 0.62	15 36 281 31 36 67 62 21 21 15 12 19 15	3.8% 6.8% 51.6% 6.7% 13.1% 8.3% 5.2% 4.3% 3.3% 5.3% 3.8%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.38 [-0.22, 1.00] 0.44 [-0.07, 1.69] 0.39 [-0.43, 1.01] 0.51 [-0.07, 1.69] 0.31 [-0.57, 0.64] 1.21 [0.42, 2.00]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J.2014 Subtotal (95% CI) Heterogeneliy: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J.2013 Zhanhai Dong 2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Ioanal Ilyes 2023 (14%Doxycycline) Ioanal Ilyes 2023 (14%D	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1 1.1 0.3 2.22 2.9 df = 6 (P	$\begin{array}{c} 0.4\\ 0.71\\ \end{array}$ = 0.00 $\begin{array}{c} 1.08\\ 1.28\\ = 0.39);\\ \begin{array}{c} 1.07\\ 0.6\\ 0.54\\ 0.655\\ 0.31\\ 1.69\\ 0.5 \end{array}$	11 36 278 1): $ ^2 =$ 33 36 69 $ ^2 = 09$ 62 21 21 15 10 23 15 167	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.85 0.85 0.85 0.01 2.17 2.2	0.5 0.82 0.94 1.59 0.61 0.61 0.676 0.67 1.56 0.62	15 36 281 31 36 67 62 21 21 15 12 19 15	3.8% 6.8% 51.6% 6.7% 13.1% 8.3% 5.2% 4.3% 3.3% 5.3% 3.8%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.38 [-0.22, 1.00] 0.44 [-0.07, 1.69] 0.39 [-0.43, 1.01] 0.51 [-0.07, 1.69] 0.31 [-0.57, 0.64] 1.21 [0.42, 2.00]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J.2014 Subtotal (95% CI) Heterogeneliy: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J.2013 Zhanhai Dong 2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Ioana Ilyes 2023 (14%Doxycycline) Ioana Ioana Ioan	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1 1.1 0.3 2.22 2.9 df = 6 (P	$\begin{array}{c} 0.4\\ 0.71\\ \end{array}$ = 0.00 $\begin{array}{c} 1.08\\ 1.28\\ = 0.39);\\ \begin{array}{c} 1.07\\ 0.6\\ 0.54\\ 0.655\\ 0.31\\ 1.69\\ 0.5 \end{array}$	11 36 278 1): $ ^2 =$ 33 36 69 $ ^2 = 09$ 62 21 21 15 10 23 15 167	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.85 0.85 0.85 0.01 2.17 2.2	0.5 0.82 0.94 1.59 0.61 0.61 0.676 0.67 1.56 0.62	15 36 281 31 36 67 62 21 21 15 12 19 15	3.8% 6.8% 51.6% 6.7% 13.1% 8.3% 5.2% 4.3% 3.3% 5.3% 3.8%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.38 [-0.22, 1.00] 0.44 [-0.07, 1.69] 0.39 [-0.43, 1.01] 0.51 [-0.07, 1.69] 0.31 [-0.57, 0.64] 1.21 [0.42, 2.00]	
Thomas F. Flemming (1.25%) 2011 Yaghini J.2014 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.16; Ch <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J.2013 Zhanhai Dong 2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Ioana Ilyes 2023 (14%Doxycycline) Ioana Ilyes 2023 (14%Doxycycline) Ioana Ilyes 2023 (14%Doxycycline) Ioana Ilyes 2023 (Piperacillin) Kuldeep S. Patil 2022 Paula Matesanz 2013 Rattanasuwan, K 2016 Taalab, M. R 2021 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.01; Ch <sup>2</sup> = 6.43, Test for overall effect: Z = 3.59 (P = 0.00 2.3.4 Twelve Months	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1 1.1 0.3 2.22 2.9 df = 6 (P	$\begin{array}{c} 0.4\\ 0.71\\ \end{array}$ = 0.00 $\begin{array}{c} 1.08\\ 1.28\\ = 0.39);\\ \begin{array}{c} 1.07\\ 0.6\\ 0.54\\ 0.655\\ 0.31\\ 1.69\\ 0.5 \end{array}$	11 36 278 1): $ ^2 =$ 33 36 69 $ ^2 = 09$ 62 21 21 15 10 23 15 167	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.85 0.85 0.85 0.01 2.17 2.2	0.5 0.82 0.94 1.59 0.61 0.61 0.676 0.67 1.56 0.62	15 36 281 31 36 67 62 21 21 15 12 19 15	3.8% 6.8% 51.6% 6.7% 13.1% 8.3% 5.2% 4.3% 3.3% 5.3% 3.8%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.38 [-0.22, 1.00] 0.43 [-0.19, 1.04] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01] 0.81 [-0.07, 1.69] 0.03 [-0.55]	
Thomas F. Flemming (1.25%) 2011 Yaghini J.2014 Subtotal (95% CI) Heterogeneliy: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J.2013 Zhanhai Dong 2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Joana Ilyes 2023 (14%Doxycycline) Joana Ilyes 2023 (14%Doxy	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1 1.1 0.3 2.22 2.9 df = 6 (P 03) 0.5	0.4 0.71 P = 0.00 1.08 1.28 = 0.39); 1.07 0.6 0.54 0.655 0.31 1.65 0.5 0.5 0.5 1.85	11 36 278 1);   <sup>2</sup> = 33 36 69   <sup>2</sup> = 0? 62 21 21 15 10 23 15 167 1 <sup>2</sup> = 7? 50	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.85 0.85 0.85 0.85 0.85	0.5 0.82 0.94 1.59 0.61 0.67 0.67 0.67 0.37 1.56 0.62	15 36 281 31 36 67 62 21 21 15 12 21 19 15 15 50	3.8% 6.8% 51.6% 6.7% 13.1% 8.3% 5.2% 5.2% 5.2% 3.3% 3.3% 3.8% 35.3%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.39 [-0.22, 1.00] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01] 0.21 [-0.43, 1.01] 0.30 [-0.58, 0.64] 1.21 [0.42, 2.00] 0.42 [0.19, 0.65] 0.08 [-0.32, 0.47]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J.2014 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.16; Ch <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J.2013 Zhanhai Dong 2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Ioana Ilyes 2023 (Hipboxycoline) Ioana Ilyes 2023 (Piperacillin) Kuldeep S. Patil 2022 Paula Matesanz 2013 Rattanasuwan, K 2016 Taalab, M. R 2021 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 6.43, Test for overall effect: Z = 3.59 (P = 0.00 2.3.4 Tweive Months Andrea Pilloni 2022	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1 1 1 0.3 2.22 2.9 df = 6 (P 03) 0.5 0.39	$\begin{array}{c} 0.4\\ 0.71\\ \end{array}$	11 36 278 1);   <sup>2</sup> = 33 36 69   <sup>2</sup> = 09 62 21 15 10 23 15 167   <sup>2</sup> = 79 50 21	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.85 0.81 2.17 2.2 6	0.5 0.82 0.94 1.59 0.61 0.61 0.67 1.56 0.62	15 36 281 31 36 67 62 21 21 21 21 15 12 19 15 5	3.8% 6.8% 51.6% 6.7% 13.1% 8.3% 5.2% 5.2% 5.2% 5.2% 5.3% 3.3% 3.3% 3.3% 3.3%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.63 [0.31, 0.96] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.39 [-0.22, 1.00] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01] 0.41 [-0.07, 1.69] 0.03 [-0.58, 0.64] 1.21 [0.42, 2.00] 0.42 [0.19, 0.65] 0.08 [-0.32, 0.47] -0.40 [-1.01, 0.21]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J 2014 Subiotal (85% CI) Heterogeneity: Tau <sup>2</sup> = 0.16; Ch <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J 2013 Zhanhai Dong 2012 Subiotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Ioana Ilyes 2023 (Piperacillin) Kuldeep S. Patil 2022 Paula Matesanz 2013 Rattanasuwan, K 2016 Taalab, M. R 2021 Subiotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.01; Ch <sup>2</sup> = 6.43, Test for overall effect: Z = 3.59 (P = 0.00 2.3.4 Twelve Months Andrea Pilioni 2022 Viorella Radulescu (1%CHX) 2022	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1 1.1 0.3 2.22 2.9 df = 6 (P 03) 0.5	0.4 0.71 P = 0.00 1.08 1.28 = 0.39); 1.07 0.6 0.54 0.655 0.31 1.65 0.5 0.5 0.5 1.85	11 36 278 1);   <sup>2</sup> = 33 36 69   <sup>2</sup> = 0? 62 21 21 15 10 23 15 167 1 <sup>2</sup> = 7? 50	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.85 0.85 0.85 0.85 0.85	0.5 0.82 0.94 1.59 0.61 0.67 0.67 0.67 0.37 1.56 0.62	15 36 281 31 36 67 62 21 15 12 15 15 15 15 15 15 50 21	3.8% 6.8% 51.6% 6.7% 13.1% 8.3% 5.2% 5.2% 5.2% 3.3% 3.3% 3.8% 35.3%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.88] 0.43 [-0.04, 0.88] 0.43 [-0.04, 0.89] 0.43 [-0.04, 0.89] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.39 [-0.22, 1.00] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01] 0.41 [-0.07, 1.89] 0.30 [-0.58, 0.64] 1.21 [0.42, 2.00] 0.42 [0.19, 0.65] 0.08 [-0.32, 0.47] -0.40 [-1.01, 0.21] 0.28 [-0.32, 0.89]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J.2014 Subtotal (95% CI) Heterogeneily: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J.2013 Zhanhai Dong 2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Ioana Ilyes 2023 (14%Doxycycline) Ioana Ilyes 2015 (Thiprae 6.43, Test for overall effect: Z = 3.59 (P = 0.00 2.3.4 Twelve Months Andrea Pilloni 2022 Vioreila Radulescu (1%CHX) 2022 Vioreila Radulescu (1%CHX	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1 1 1 0.3 2.22 2.9 df = 6 (P 03) 0.5 0.39	$\begin{array}{c} 0.4\\ 0.71\\ \end{array}$	$\begin{array}{c} 11\\ 36\\ 278\\ 1); \  ^2=\\ 33\\ 36\\ 69\\  ^2=0?\\ 62\\ 21\\ 15\\ 16\\ 15\\ 16\\ 7\\  ^2=7?\\ 50\\ 21\\ 21\\ \end{array}$	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.85 0.81 2.17 2.2 6	0.5 0.82 0.94 1.59 0.61 0.61 0.67 1.56 0.62	15 36 281 31 36 67 62 21 21 15 165 50 21 21	3.8% 6.8% 51.6% 6.7% 13.1% 8.3% 5.2% 5.2% 5.2% 5.2% 5.3% 3.3% 3.3% 3.3% 3.3%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.63 [0.31, 0.96] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.39 [-0.22, 1.00] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01] 0.41 [-0.07, 1.69] 0.03 [-0.58, 0.64] 1.21 [0.42, 2.00] 0.42 [0.19, 0.65] 0.08 [-0.32, 0.47] -0.40 [-1.01, 0.21]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J.2014 Heterogeneity: Tau <sup>2</sup> = 0.16; Ch <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J.2013 Zhanhai Dong 2012 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 toana Ilyes 2023 (Piperacillin) Kuideep S. Patil 2022 Paula Matesanz 2013 Rattanasuwan, K 2016 Taalab, M. R 2021 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.01; Ch <sup>2</sup> = 6.43, Test for overall effect: Z = 3.59 (P = 0.00 2.3.4 Twelve Months Andrea Pilloni 2022 Viorelia Radulescu (NaCCl) 2022 Subtotal (95% Cl) Heterogeneity: Not applicable	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1 1 1 0.3 2.22 2.9 df = 6 (P 03) 0.5 0.39	$\begin{array}{c} 0.4\\ 0.71\\ \end{array}$	$\begin{array}{c} 11\\ 36\\ 278\\ 1); \  ^2=\\ 33\\ 36\\ 69\\  ^2=0?\\ 62\\ 21\\ 15\\ 16\\ 15\\ 16\\ 7\\  ^2=7?\\ 50\\ 21\\ 21\\ \end{array}$	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.85 0.81 2.17 2.2 6	0.5 0.82 0.94 1.59 0.61 0.61 0.67 1.56 0.62	15 36 281 31 36 67 62 21 21 15 165 50 21 21	3.8% 6.8% 51.6% 6.7% 13.1% 8.3% 5.2% 5.2% 5.2% 5.2% 5.3% 3.3% 3.3% 3.3% 3.3%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.88] 0.43 [-0.04, 0.88] 0.43 [-0.04, 0.89] 0.43 [-0.04, 0.89] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.39 [-0.22, 1.00] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01] 0.41 [-0.07, 1.89] 0.30 [-0.58, 0.64] 1.21 [0.42, 2.00] 0.42 [0.19, 0.65] 0.08 [-0.32, 0.47] -0.40 [-1.01, 0.21] 0.28 [-0.32, 0.89]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J.2014 Heterogeneity: Tau <sup>2</sup> = 0.16; Ch <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J.2013 Zhanhai Dong 2012 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 toana Ilyes 2023 (Piperacillin) Kuideep S. Patil 2022 Paula Matesanz 2013 Rattanasuwan, K 2016 Taalab, M. R 2021 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.01; Ch <sup>2</sup> = 6.43, Test for overall effect: Z = 3.59 (P = 0.00 2.3.4 Twelve Months Andrea Pilloni 2022 Viorelia Radulescu (NaCCl) 2022 Subtotal (95% Cl) Heterogeneity: Not applicable	0.8 2.25 , df = 8 (f 01) 1.13 1.57 df = 1 (P 07) 0.44 1.09 1.1 1 1 0.3 2.22 2.9 df = 6 (P 03) 0.5 0.39	$\begin{array}{c} 0.4\\ 0.71\\ \end{array}$	$\begin{array}{c} 11\\ 36\\ 278\\ 1); \  ^2=\\ 33\\ 36\\ 69\\  ^2=0?\\ 62\\ 21\\ 15\\ 16\\ 15\\ 16\\ 7\\  ^2=7?\\ 50\\ 21\\ 21\\ \end{array}$	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.85 0.81 2.17 2.2 6	0.5 0.82 0.94 1.59 0.61 0.61 0.67 1.56 0.62	15 36 281 31 36 67 62 21 21 15 165 50 21 21	3.8% 6.8% 51.6% 6.7% 13.1% 8.3% 5.2% 5.2% 5.2% 5.2% 5.3% 3.3% 3.3% 3.3% 3.3%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.88] 0.43 [-0.04, 0.88] 0.43 [-0.04, 0.89] 0.43 [-0.04, 0.89] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.39 [-0.22, 1.00] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01] 0.41 [-0.07, 1.89] 0.30 [-0.58, 0.64] 1.21 [0.42, 2.00] 0.42 [0.19, 0.65] 0.08 [-0.32, 0.47] -0.40 [-1.01, 0.21] 0.28 [-0.32, 0.89]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J.2013 Subtotal (95% CI) Heterogeneliy: Tau <sup>2</sup> = 0.16; Chi <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J.2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Ioana Ilyes 2023 (14%Doxycycline) Ioana Ilyes 2023 (14%Chi 2022 Vioreila Radulescu (1%CHX) 2022 Subtotal (95% CI) Heterogeneity: Not applicable Test for overall effect: Not applicable Total (95% CI)	0.8 2.25 01) 1.13 1.57 0.44 1.09 0.7 0.44 1.09 0.44 1.09 2.9 2.9 df = 6 (P 03) 0.5 0.39 0.7	0.4 0.71 0.71 0.6 1.08 1.28 1.28 1.07 0.6 0.54 0.655 0.31 1.69 0.5 0.5 1.69 0.5 0.38; 0.38 0.4	11 36 2778 2778 2778 2778 33 36 69 $ ^2 = 0^{\circ}$ 62 21 15 16 23 15 167 167 7 <sup>°</sup> 50 21 21 0 514	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.85 0.01 2.17 2.2 6 0.36 0.57 0.57	0.5 0.82 0.94 1.59 0.95 0.61 0.61 0.61 0.67 1.56 0.62	15 36 281 31 36 67 62 21 21 15 165 50 21 21	3.8% 6.8% 51.6% 6.7% 13.1% 8.3% 5.2% 5.2% 5.2% 4.3% 35.3% 35.3% 0.0% 0.0%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.88] 0.43 [-0.04, 0.88] 0.43 [-0.04, 0.89] 0.43 [-0.04, 0.89] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.39 [-0.22, 1.00] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01] 0.43 [-0.19, 1.04] 0.29 [-0.43, 1.01] 0.41 [-0.07, 1.89] 0.30 [-0.58, 0.64] 1.21 [0.42, 2.00] 0.42 [0.19, 0.65] 0.08 [-0.32, 0.47] -0.40 [-1.01, 0.21] 0.28 [-0.32, 0.89]	
Thomas F. Flemmig (1.25%) 2011 Yaghini J.2014 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.16; Ch <sup>2</sup> = 26.08 Test for overall effect: Z = 3.81 (P = 0.00 2.3.2 Four Months Mahendra, J.2013 Zhanhai Dong 2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.74, Test for overall effect: Z = 3.38 (P = 0.00 2.3.3 Six Months B. Vadiati Saberi 2017 Ioana Ilyes 2023 (Hipboxycoline) Ioana Ilyes 2023 (Piperacillin) Kuldeep S. Patil 2022 Paula Matesanz 2013 Rattanasuwan, K 2016 Taalab, M. R 2021 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.01; Chi <sup>2</sup> = 6.43, Test for overall effect: Z = 3.59 (P = 0.00 2.3.4 Tweive Months Andrea Pilloni 2022	0.8 2.25 (df = 8 (f 01) 1.13 1.57 (df = 1 (P 0.44 1.09 1.1 1.1 0.3 2.22 df = 6 (P 0.39 0.5 0.39 0.7 , df = 17	0.4 0.71 0.71 0.6 1.08 1.28 1.28 1.07 0.6 0.54 0.655 0.31 1.69 0.5 0.5 1.69 0.5 0.38; 0.38 0.4	11 36 278 11);   <sup>2</sup> = 33 36 69   <sup>2</sup> = 0? 62 21 15 16 23 15 167 1 <sup>2</sup> = 7? 50 21 21 0 514	0.6 1.92 69% 0.68 0.49 6 0.07 0.85 0.85 0.85 0.85 0.01 2.17 2.2 6 0.36 0.57 0.57	0.5 0.82 0.94 1.59 0.95 0.61 0.61 0.61 0.67 1.56 0.62	15 36 281 31 36 67 62 21 21 15 12 19 15 50 21 21 0	3.8% 6.8% 51.6% 6.7% 13.1% 8.3% 5.2% 5.2% 5.2% 4.3% 35.3% 35.3% 0.0% 0.0%	0.43 [-0.30, 1.15] 0.42 [-0.37, 1.21] 0.43 [-0.04, 0.89] 0.63 [0.31, 0.96] 0.63 [0.31, 0.96] 0.44 [-0.06, 0.93] 0.74 [0.26, 1.22] 0.59 [0.25, 0.94] 0.36 [0.01, 0.72] 0.38 [-0.22, 1.00] 0.43 [-0.19, 1.04] 0.28 [-0.23, 0.41] 1.21 [0.42, 2.00] 0.42 [0.19, 0.65] 0.08 [-0.32, 0.47] -0.40 [-1.10, 0.21] 0.28 [-0.33, 0.89] Not estimable	

Fig. 7: Sensitivity analysis of included studies in which the outcome index was CAL. (a) Overall study sensitivity analysis of CAL; (b) Sensitivity analysis of follow-up time for CAL

# Discussion

Subgingival scaling and root planing are effective surgical methods for treating periodontitis, and they can completely remove calculus and plaque microorganisms from the cementum surface (37). Periodontal infection can be controlled by reducing the number of Gram-negative anaerobic bacteria in plaques (38). Moreover, systemic or local antibiotics can enhance local infection control in patients with periodontitis, and periodontal drugassisted mechanical debridement can enhance the clinical outcomes of periodontitis treatment. Notably, topical drugs have high specificity, minor side effects, and better patient compliance, making them preferable in clinical treatment (39, 40). Gel drugs are often selected based on their biocompatible gel materials (i.e., chitosan gel (41) and hyaluronic acid gel (42) that can serve as carriers for loading various drugs, such as antibiotics (43) and antitumor drugs (44). The mechanism of action of gel drugs in the treatment of chronic periodontitis can be divided into four categories: Firstly, antibiotics such as doxycycline can bind specifically to bacterial ribosomes, preventing bacterial peptide chain extension and altering bacterial cell membrane permeability, thereby inhibiting bacterial DNA replication (45). Secondly, oral bacteriostatic agents or fungicides, such as chlorhexidine, can destroy the cell membrane and inhibit bacterial dehydrogenase activity, leading to bacteriostasis or sterilization (46). Thirdly, plant extracts exhibit anti-inflammatory effects. For example, green tea catechins have been found to inhibit LPS-mediated inflammation (47). Lastly, gel formulations incorporating bone-promoting ingredients, such as hydroxyapatite, can help inhibit alveolar bone resorption. However, current clinical gel drugs face several challenges, including issues related to the drug matrix, loading concentration, and loading type. In this study, a meta-analysis was conducted to evaluate the application of gel-based local drug delivery systems as adjuvant treatment for perio-

dontitis, with PPD and CAL as clinical indicators.

We observed that the treatment effect was better in the experimental group with adjuvant gel drugs than in the control group with SRP alone. The adjuvant application of gel drugs is more advantageous than traditional non-surgical treatments in terms of reducing PPD and stabilizing the periodontal attachment level. Among the two outcome measures used in this study, the main sources of heterogeneity were identified as the studies by Gupta R (21) and Kadadasu R (27). We believe that the main reasons for the difference are as follows: Firstly, Gupta applied two gels: a 10% doxycycline hydrochloride gel and a 1.5% xanthan gum-based chlorhexidine gel. The doxycycline and chlorhexidine concentrations in Gupta's study were higher than those in other studies, potentially contributing to divergent treatment outcomes. Secondly, in the studies by Gupta R and Kadadasu R, the gel matrix could be transformed into sol-gel, enhancing the adhesion of the gel within the periodontal pocket. Thirdly, ibuprofen was included in the moxifloxacin gel in the experimental group in the study by Kadadasu. The addition of ibuprofen likely exerted synergistic effects on sterilization, antiinflammation, and osteogenesis of moxifloxacin. Additionally, some gels have limitations in the treatment of chronic periodontitis. For example, the gel drugs used by Rassameemasmaung (32) and Rattanasuwan(33) were derived from green tea and mangosteen bark extracts. In the early treatment stages, the CAL results in both studies showed no significant differences between the experimental and control groups. Compared with antibiotics, plant extracts have lower biological toxicity and are less prone to the development of drug-resistant strains. However, due to their low specificity towards pathogenic bacteria, the efficacy of plant extracts in treating periodontitis is generally weaker than that of antibiotics. This discrepancy may be attributed to the gentle and stable nature of plant extracts during long-term treatments. Notably, no significant difference was observed between 0.4% and 1.25% moxifloxacin and ibuprofen gels in the treatment of chronic periodontitis (23). The pathogenic bacteria associated with chronic periodontitis may have some resistance to moxifloxacin, highlighting a significant challenge in the antibiotic treatment of chronic periodontitis. Finally, there was variation in the selection of the study population among the included studies. Although the PPD of patients with periodontitis selected in most studies was between 3 and 8 mm, only two studies (32, 33) including patients with a PPD >8 mm.

Finally, the significant impact of the 12-month follow-up results on heterogeneity in the subgroup analysis. This observation may be attributed to the fact that the periodontal conditions of patients gradually stabilize at 12 months. Consequently, the changes in PPD and CAL caused by the clinical treatment gradually decrease. Moreover, when the follow-up time was three months, the depth of the periodontal probe and the CAL of the patients showed the most significant changes. Therefore, 3 months can be used as a crucial time point for the clinical evaluation of patients with chronic periodontitis.

In clinical practice, patient compliance can be reduced for several reasons. High-quality studies with an adequate number of patients and longer follow-up periods are needed to provide reliable and accurate scientific guidance for the application of gel-based drugs in the adjuvant treatment of periodontitis. Patients with periodontitis who receive active treatment and have periodontal pocket probing depths  $\leq 4$  mm should be followed up for > 12 months to ensure that the periodontal attachment levels are stable (48). This recommendation aligns with the findings from the subgroup analysis of follow-up time in this study. Moreover, gel-based drug-assisted SRP is a more effective treatment approach for periodontitis than SRP alone. However, differences in drug matrix, loading concentration, and types can significantly affect the scientific application of gel drugs. Therefore, high-quality long-term studies are needed to obtain evidence that is more scientific. Furthermore, there is a need for a unified and standardized method in selecting study participants, implementing biosafety measurements of the drug, and determining appropriate drug dosage. Additionally, to enhance the quality of studies and provide more scientific evidence for gel-based drug-assisted periodontitis treatment, it is necessary to establish a reference standard for cross-sectional comparisons with similar studies while exploring the effects of different drugs on the efficiency of periodontitis treatment. This approach will contribute to advancing the field and facilitating evidence-based decision-making in the clinical management of periodontitis.

# Conclusion

The application of drug-loaded gel as adjunctive therapy for periodontitis effectively reduced PPD and promoted CAL recovery. These findings provide evidence-based support for the enhanced efficacy, security, and rational use of drug-loaded gels in the clinical management of periodontitis.

# Journalism Ethics considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

# Funding

The study was supported by Natural Science Foundation of Gansu Province under Grant number 23JRRA1080, Lanzhou Science and Technology Project under Grant number 2020-XG-36 and Project Commissioned by Enterprises and Institutions of School of Stomatology, Lanzhou University under Grant number 20220832.

# Acknowledgements

We would like to thank the funder for his assistance and guidance in this research. The author also cordially thanks Professor Yang Kehu and Dr. Li Yanfei from the Research Center for Evidence-Based Medicine of Lanzhou University in Gansu Province for their technical support.

# Availability of data

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

# **Competing interests**

The authors declare that they have no competing interests.

### References

- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392(10159): 1789–1858.
- Chen M, Cai W (2019). Oxidative stress-related biomarkers in saliva and gingival crevicular fluid associated with chronic periodontitis: A systematic review and meta-analysis. J Clin Periodontol, 46(6): 608–622.
- Kavarthapu A, Gurumoorthy K (2021). Linking chronic periodontitis and oral cancer: A review. Oral Oncol, 121: 105375.
- Wang RP, Ho YS (2019). Systemic inflammation linking chronic periodontitis to cognitive decline. *Brain Behav Immun*, 81: 63–73.
- 5. Sayed EN, Baeumer A (2019). Twenty years later: Oral health-related quality of life and standard of treatment in patients with chronic periodontitis. *J Periodontol*, 90(4): 323–330.
- Ilango P, Mahendra J (2021). Evidence linking the role of periodontal viruses in coronary artery disease with and without periodontitis. *J Periodontol*, 92(1): 113–122.
- Takeguchi A, Miyazawa, K (2021). Effects of a β2-adrenergic receptor blocker on experimental periodontitis in spontaneously hypertensive rats. *Life Sci*, 277: 119593.
- Choi S, Kim K (2019). Association of Chronic Periodontitis on Alzheimer's Disease or Vascular Dementia. J Am Geriatr Soc, 67(6): 1234–1239.
- 9. Fleury V, Zekeridou A (2021). Oral Dysbiosis

and Inflammation in Parkinson's Disease . J Parkinsons Dis, 11(2): 619-31.

- Zhao X, Yang Y (2022). Injectable hydrogels with high drug loading through B-N coordination and ROS-triggered drug release for efficient treatment of chronic periodontitis in diabetic rats. *Biomaterials*, 282: 121387.
- AlSakr A, Blanchard S (2021). Association between intracranial carotid artery calcifications and periodontitis: A cone-beam computed tomography study. J Periodontol, 92(10): 1402–1409.
- Liu M, Liu Q (2021). LncRNA LTSCCAT promotes tongue squamous cell carcinoma metastasis via targeting the miR-103a-2-5p/SMYD3/TWIST1 axis. *Cell Death Dis*, 12(2): 144.
- 13. Yao Y, Shen X (2021). Periodontal Pathogens Promote Oral Squamous Cell Carcinoma by Regulating ATR and NLRP3 Inflammasome. *Front Oncol*, 11: 722797.
- D'Aiuto F, Gkranias N (2018). Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. *Lancet Diabetes Endocrinol*, 6(12): 954–965.
- 15. Kaku M, Matsuda S (2021). Generalized periodontitis treated with periodontal, orthodontic, and prosthodontic therapy: A case report. *World J Clin Cases*, 9(21): 6110–6124.
- 16. Fang F, Gao B (2021). Efficacy of root canal therapy combined with basic periodontal therapy and its impact on inflammatory responses in patients with combined periodontal-endodontic lesions. *Am J Transl Res*, 13(12): 14149–14156.
- Cecoro G, Piccirillo A (2021). Efficacy of locally delivered statins as an adjunct to scaling and root planning in the treatment of periodontitis: a systematic review and metaanalysis. *Eur Rev Med Pharmacol Sci*, 25(18): 5737–5754.
- Pretzl B, Sälzer S (2019). Administration of systemic antibiotics during non-surgical periodontal therapy-a consensus report. *Clin Oral Investig*, 23(7): 3073–3085.
- 19. Almoshari Y, Ren R (2020). GSK3 inhibitorloaded osteotropic Pluronic hydrogel effectively mitigates periodontal tissue

damage associated with experimental periodontitis. *Biomaterials*, 261: 120293.

- 20. Naga K, Ideguchi H (2020). An injectable hydrogel-formulated inhibitor of prolyl-4hydroxylase promotes T regulatory cell recruitment and enhances alveolar bone regeneration during resolution of experimental periodontitis. *FASEB J*, 34(10): 13726–13740.
- Gupta R, Pandit N (2008). Comparative evaluation of subgingivally delivered 10% doxycycline hyclate and xanthan-based chlorhexidine gels in the treatment of chronic periodontitis. J Contemp Dent Pract, 9(7): 25–32.
- Ilyes I, Rusu D (2023). A Placebo-Controlled Trial to Evaluate Two Locally Delivered Antibiotic Gels (Piperacillin Plus Tazobactam vs. Doxycycline) in Stage III-IV Periodontitis Patients. *Medicina (Kaunas)*, 59(2): 303.
- 23. Flemmig TF, Petersilka G (2011). Efficacy and safety of adjunctive local moxifloxacin delivery in the treatment of periodontitis. *J Periodontol*, 82(1): 96–105.
- 24. Radulescu V, Boariu MI (2022). Clinical and microbiological effects of a single application of sodium hypochlorite gel during subgingival re-instrumentation: a triple-blind randomized placebo-controlled clinical trial. *Clin Oral Investig*, 26(11): 6639–6652.
- Liang FZ, Wang JL (2020). Effect of ultrasonic subgingival scaling combined with hyaluronic acid gel treatment on the efficacy of periodontitis and the expression of CRP and VEGF in the elderly. *Chinese Journal of Gerontology*, 40(19): 4146-4149.
- Dong ZH, Shi SG (2012). Application of slowrelease chlorhexidine gel in the treatment of chronic periodontitis. *Journal of Endodontics and Periodontology*. 22(10): 594-6.
- 27. Kadadasu R, Atchuta A (2020). Clinicomicrobiological evaluation of the efficacy of local delivery of moxifloxacin and ibuprofen gel as an adjunct to scaling and root planing in chronic periodontitis patients. J Oral Maxillofac Pathol, 24(1): 26–32.
- Mahendra J, Mahendra L (2013). Clinical effects of subgingivally delivered spirulina gel in chronic periodontitis cases: a placebo controlled clinical trial. J Clin Diagn Res, 7(10): 2330–2333.
- 29. Matesanz P, Herrera D (2013). A randomized

clinical trial on the clinical and microbiological efficacy of a xanthan gel with chlorhexidine for subgingival use. *Clin Oral Investig*, 17(1): 55–66.

- Patil KS, Mahajani M (2022). Efficacy of 1.5% Metformin Gel as an Adjuvant to Scaling, Root Planing, and Curettage for the Treatment of Infrabony Defects in Chronic Periodontitis Patients. *Contemp Clin Dent*, 13(1): 18–23.
- 31. Pilloni A, Rojas MA (2023). Clinical effects of the adjunctive use of polynucleotide and hyaluronic acid-based gel in the subgingival re-instrumentation of residual periodontal pockets: A randomized, split-mouth clinical trial. *J Periodontol*, 94(3): 354–363.
- Rassameemasmaung S, Sirikulsathean A (2008). Topical application of Garcinia mangostana L. pericarp gel as an adjunct to periodontal treatment. *Complement Ther Med*, 16(5): 262– 267.
- Rattanasuwan K, Rassameemasmaung S (2016). Clinical effect of locally delivered gel containing green tea extract as an adjunct to non-surgical periodontal treatment. Odontology, 104(1): 89–97.
- Saberi BV, Radafshar G (2017). Effect of Topical Gel Chlorhexidine 0.2% on Non-Surgical Treatment of Chronic Periodontitis. J Babol Univ Med Sci, 19: 74-80.
- 35. Taalab MR, Mahmoud SA (2021). Intrapocket application of tea tree oil gel in the treatment of stage 2 periodontitis. *BMC Oral Health*, 21(1): 239.
- 36. Yaghini J, Shahabooei M (2014). Efficacy of a local-drug delivery gel containing extracts of Quercus brantii and Coriandrum sativum as an adjunct to scaling and root planing in moderate chronic periodontitis patients. J Res Pharm Pract, 3(2): 67–71.
- Daly CG, Kieser J (1979). Cementum involved in periodontal disease: a review of its features and clinical management. J Dent, 7(3): 185– 193.
- Mombelli A, Nyman S (1995). Clinical and microbiological changes associated with an altered subgingival environment induced by periodontal pocket reduction. J Clin Periodontol, 22(10): 780–787.
- 39. Bogren A, Teles RP (2008). Locally delivered doxycycline during supportive periodontal

therapy: a 3-year study. J Periodontol, 79(5): 827–835.

- Rajeshwari HR, Dhamecha D (2019). Local drug delivery systems in the management of periodontitis: A scientific review. J Control Release, 307: 393–409.
- 41. Medellín-Castillo NA, Isaacs-Páez ED (2021). Formaldehyde and tripolyphosphate crosslinked chitosan hydrogels: Synthesis, characterization and modeling. *Int J Biol Macromol*, 183: 2293–2304.
- 42. Lou J, Stowers R (2018). Stress relaxing hyaluronic acid-collagen hydrogels promote cell spreading, fiber remodeling, and focal adhesion formation in 3D cell culture. *Biomaterials*, 154: 213–222.
- Hemmingsen LM, Julin K (2021). Chitosomes-In-Chitosan Hydrogel for Acute Skin Injuries: Prevention and Infection Control. *Mar Drugs*, 19(5): 269.
- 44. Sagbas SS, Ari B (2019). Hyaluronic acid and

hyaluronic acid: Sucrose nanogels for hydrophobic cancer drug delivery. *Int J Biol Macromol*, 126: 1150–1157.

- 45. Lecio G, Ribeiro FV (2020). Novel 20% doxycycline-loaded PLGA nanospheres as adjunctive therapy in chronic periodontitis in type-2 diabetics: randomized clinical, immune and microbiological trial. *Clin Oral Investig*, 24(3): 1269–1279.
- Brooke ZLS, Belfield LA (2021). Effects of chlorhexidine mouthwash on the oral microbiome. J Dent, 113: 103768.
- Azambuja JH, Mancuso RI (2022). Protective effect of green tea and epigallocatechin-3gallate in a LPS-induced systemic inflammation model. J Nutr Biochem, 101: 108920.
- Loos BG, Needleman I (2020). Endpoints of active periodontal therapy. J Clin Periodontol, 47 Suppl 22(Suppl 22):61-71.